coronary artery atherosclerosis is, multifactorial, complex disease locally, and a major cause of death in the United States. complex interaction between transport biochemical and biomechanical forces affecting the growth of the disease.
Wall shear stress (WSS) influence coronary artery atherosclerosis by inducing endothelial cell mechanotransduction and by controlling the near-wall transport processes involved in atherosclerosis. Each process is controlled by a different WSS and because it has complicated the interpretation of WSS in atherosclerosis. In this paper, we present a comprehensive theory for WSS in atherosclerosis.
First, a brief review of mechanotransduction shear stress-mediated atherosclerosis is presented. Next, a special subject of computational fluid dynamics (CFD) simulations performed on ten models of coronary artery diseased subjects and healthy. Specific biochemical mass transportation models developed for the study of low-density lipoprotein, nitric oxide, adenosine triphosphate, oxygen, monocyte chemoattractant protein-1, and transportation monocytes.
Results of transport compared to vector WSS and WSS Lagrangian coherent structures (WSS LCS). WSS high magnitude protected against atherosclerosis by increasing production or biochemical flux atheroprotective and reduce localization near-wall biochemistry atherogenic.
The amount of lower WSS promoted atherosclerosis by increasing localization of biochemical atherogenic. Finally, it’s interesting roles WSS SKB more complex where he was promoted or prevented by different biochemical atherosclerosis. We present a summary of the different pathways by which the WSS affect coronary artery atherosclerosis and compare mechanotransduction and biotransport different mechanisms.
Development of volatile organic compounds and their glycosylated precursors in tamarillo (Solanum betaceum Cav.) During fruit ripening: A prediction of biochemical pathways
key metabolites and pathways flavor-regulation in tamarillo investigated to explore the development of a free and glycosylation of volatile organic compounds (VOCs) during fruit ripening. The concentration of VOC-free and bound was determined by analysis by gas chromatography-mass spectrometry. Changes in physical parameters, the concentration of flavor precursors and key endogenous enzyme activity was also monitored.
A total of 22 VOC-free identified with C6 alcohols and esters into the main compound. Of the 83 VOCs detected glycosylation, phenols and terpenoids are the dominant component. The total concentration of VOCs is bound to increase up to four times during the ripening of fruit. Lipoxygenase pathway is confirmed as an important biosynthetic mechanism for the generation of VOC free and glycosylation during maturation tamarillo. This biosynthetic pathway is highly correlated with the activity of key enzymes and content of the substrate, especially of linolenic acid (p <0.05 or p <0.01).
Phenotypic, genotypic and biochemical changes during the selection of pyrethroid resistance in Anopheles gambiae mosquitoes
Directional Selection for insecticide resistance due to the indiscriminate use of insecticides in public health and agriculture system favors increased frequency of insecticide-resistant alleles in natural populations. Similarly, the removal of the selection pressure generally leads to rot in the resistance. recent investigations on the emergence of insecticide resistance in mosquitoes largely rely on field surveys resistance in vector populations that typically have a complex history of exposure to a variety of public health insecticides and pest control agricultural in nature, and thus the effects of certain insecticides on resistance levels level of emergency or resistance to decay unknown.
This study examined the phenotypic, genotypic, and biochemical changes that occur during the selection process for pyrethroid resistance in Anopheles gambiae, the most important vector of malaria in Africa. In parallel, we also examined the changes in the population hold when there is no selection pressure is applied.
Through repeated deltamethrin selection in adult mosquitoes from field populations collected in western Kenya for 12 generations, we obtain three independent and highly pyrethroid resistant An. gambiae populations. Three vulnerable populations from the same parent population is generated by removing the selection pressure.
Second row mosquito populations differ significantly in monooxygenases and beta-esterase activity, but not in Vgsc frequency of gene mutations, suggesting a metabolic detoxification mechanisms play a major role in generating resistance moderate intensity or high intensity resistance. Pre-exposure synergist piperonyl butoxide restored susceptibility to insecticides among highly resistant mosquitoes, confirming the role of monooxygenases in pyrethroid resistance.
The level of damage resistance to be fully susceptible of moderate intensity resistance took 15 generations, to support at least 2-year interval is required when using the rotation of insecticides with different modes of action to be considered for resistance management.
Biochemical parameters in Cognitive Function
cognitive impairment is a common disease. Many studies tried to elucidate the mechanisms of this dysfunction establishment, including the correlation between cognitive function and biochemical parameters. The scientists are looking for substances that will be an indicator of cognitive function and that can be determined in the cerebrospinal fluid or blood from subjects. Until now, they have isolated several such substances; However, research on the specificity of their validity and the possibility of their use in diagnostic and prognostic assessment is still ongoing.
However, there are only a few reports in the literature systematize the existing knowledge about this, and they are mostly associated with Alzheimer’s disease, not cognition in general, or refer only to certain groups of substances. This article discusses the most important biochemical exponent of cognitive function.
GALNT4 Antibody |
|||
DF13031-100ul | Affinity Biosciences | 100ul | EUR 280 |
GALNT4 Antibody |
|||
DF13031-200ul | Affinity Biosciences | 200ul | EUR 350 |
anti- GALNT4 antibody |
|||
FNab03324 | FN Test | 100µg | EUR 658.5 |
Description: Antibody raised against GALNT4 |
GALNT4 siRNA |
|||
20-abx917540 | Abbexa |
|
|
GALNT4 siRNA |
|||
20-abx917541 | Abbexa |
|
|
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
abx233324-100ug | Abbexa | 100 ug | EUR 610.8 |
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
20-abx116519 | Abbexa |
|
|
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
abx025629-400ul | Abbexa | 400 ul | EUR 627.6 |
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
abx025629-80l | Abbexa | 80 µl | EUR 343.2 |
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
abx036817-100ug | Abbexa | 100 ug | EUR 469.2 |
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
abx122500-100ug | Abbexa | 100 ug | EUR 469.2 |
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
20-abx003143 | Abbexa |
|
|
GALNT4 Rabbit pAb |
|||
A4243-100ul | Abclonal | 100 ul | EUR 369.6 |
GALNT4 Rabbit pAb |
|||
A4243-200ul | Abclonal | 200 ul | EUR 550.8 |
GALNT4 Rabbit pAb |
|||
A4243-20ul | Abclonal | 20 ul | Ask for price |
GALNT4 Rabbit pAb |
|||
A4243-50ul | Abclonal | 50 ul | Ask for price |
GALNT4 cloning plasmid |
|||
CSB-CL836662HU-10ug | Cusabio | 10ug | EUR 451.2 |
Description: A cloning plasmid for the GALNT4 gene. |
GALNT4 Blocking Peptide |
|||
33R-1400 | Fitzgerald | 100 ug | EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GALNT4 antibody, catalog no. 70R-7245 |
GALNT4 Blocking Peptide |
|||
33R-9559 | Fitzgerald | 100 ug | EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GALNT4 antibody, catalog no. 70R-7248 |
GALNT4 Blocking Peptide |
|||
DF13031-BP | Affbiotech | 1mg | EUR 234 |
GALNT4 ELISA KIT|Human |
|||
EF009763 | Lifescience Market | 96 Tests | EUR 826.8 |
Mouse Galnt4 ELISA KIT |
|||
ELI-27156m | Lifescience Market | 96 Tests | EUR 1038 |
Human GALNT4 ELISA KIT |
|||
ELI-30796h | Lifescience Market | 96 Tests | EUR 988.8 |
Human GALNT4 shRNA Plasmid |
|||
20-abx955721 | Abbexa |
|
|
Mouse GALNT4 shRNA Plasmid |
|||
20-abx970459 | Abbexa |
|
|
GALNT4 Recombinant Protein (Rat) |
|||
RP202175 | ABM | 100 ug | Ask for price |
GALNT4 Recombinant Protein (Human) |
|||
RP012883 | ABM | 100 ug | Ask for price |
GALNT4 Recombinant Protein (Mouse) |
|||
RP135836 | ABM | 100 ug | Ask for price |
Galnt4 ORF Vector (Rat) (pORF) |
|||
ORF067393 | ABM | 1.0 ug DNA | EUR 607.2 |
GALNT4 (N-term) Rabbit pAb |
|||
E2611166 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
GALNT4 ORF Vector (Human) (pORF) |
|||
ORF004295 | ABM | 1.0 ug DNA | EUR 114 |
Galnt4 ORF Vector (Mouse) (pORF) |
|||
ORF045280 | ABM | 1.0 ug DNA | EUR 607.2 |
Human GALNT4 Protein Lysate 20ug |
|||
IHUGALNT4PLLY20UG | Innovative research | each | EUR 213 |
Description: Human GALNT4 Protein Lysate 20ug |
Galnt4 sgRNA CRISPR Lentivector set (Rat) |
|||
K7515601 | ABM | 3 x 1.0 ug | EUR 406.8 |
Galnt4 3'UTR GFP Stable Cell Line |
|||
TU254930 | ABM | 1.0 ml | Ask for price |
Galnt4 3'UTR GFP Stable Cell Line |
|||
TU156887 | ABM | 1.0 ml | Ask for price |
GALNT4 3'UTR GFP Stable Cell Line |
|||
TU058523 | ABM | 1.0 ml | EUR 2799.6 |
GALNT4 sgRNA CRISPR Lentivector set (Human) |
|||
K0835401 | ABM | 3 x 1.0 ug | EUR 406.8 |
Galnt4 sgRNA CRISPR Lentivector set (Mouse) |
|||
K3418201 | ABM | 3 x 1.0 ug | EUR 406.8 |
GALNT4 Protein Vector (Rat) (pPM-C-HA) |
|||
PV269572 | ABM | 500 ng | EUR 723.6 |
GALNT4 Protein Vector (Rat) (pPB-C-His) |
|||
PV269570 | ABM | 500 ng | EUR 723.6 |
GALNT4 Protein Vector (Rat) (pPB-N-His) |
|||
PV269571 | ABM | 500 ng | EUR 723.6 |
GALNT4 Protein Vector (Rat) (pPM-C-His) |
|||
PV269573 | ABM | 500 ng | EUR 723.6 |
GALNT4 Protein Vector (Human) (pPM-C-HA) |
|||
PV017179 | ABM | 500 ng | EUR 394.8 |
GALNT4 Protein Vector (Mouse) (pPM-C-HA) |
|||
PV181120 | ABM | 500 ng | EUR 723.6 |
GALNT4 Protein Vector (Human) (pPB-C-His) |
|||
PV017177 | ABM | 500 ng | EUR 394.8 |
GALNT4 Protein Vector (Human) (pPB-N-His) |
|||
PV017178 | ABM | 500 ng | EUR 394.8 |
GALNT4 Protein Vector (Human) (pPM-C-His) |
|||
PV017180 | ABM | 500 ng | EUR 394.8 |
GALNT4 Protein Vector (Mouse) (pPB-C-His) |
|||
PV181118 | ABM | 500 ng | EUR 723.6 |
GALNT4 Protein Vector (Mouse) (pPB-N-His) |
|||
PV181119 | ABM | 500 ng | EUR 723.6 |
GALNT4 Protein Vector (Mouse) (pPM-C-His) |
|||
PV181121 | ABM | 500 ng | EUR 723.6 |
GALNT4 3'UTR Luciferase Stable Cell Line |
|||
TU008523 | ABM | 1.0 ml | EUR 2799.6 |
Galnt4 3'UTR Luciferase Stable Cell Line |
|||
TU106887 | ABM | 1.0 ml | Ask for price |
Galnt4 3'UTR Luciferase Stable Cell Line |
|||
TU204930 | ABM | 1.0 ml | Ask for price |
Galnt4 sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
K7515602 | ABM | 1.0 ug DNA | EUR 184.8 |
Galnt4 sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
K7515603 | ABM | 1.0 ug DNA | EUR 184.8 |
Galnt4 sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
K7515604 | ABM | 1.0 ug DNA | EUR 184.8 |
GALNT4 sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
K0835402 | ABM | 1.0 ug DNA | EUR 184.8 |
GALNT4 sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
K0835403 | ABM | 1.0 ug DNA | EUR 184.8 |
GALNT4 sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
K0835404 | ABM | 1.0 ug DNA | EUR 184.8 |
Galnt4 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
K3418202 | ABM | 1.0 ug DNA | EUR 184.8 |
Galnt4 sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
K3418203 | ABM | 1.0 ug DNA | EUR 184.8 |
Galnt4 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
K3418204 | ABM | 1.0 ug DNA | EUR 184.8 |
GALNT4 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
LV638647 | ABM | 1.0 ug DNA | EUR 818.4 |
GALNT4 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
LV638651 | ABM | 1.0 ug DNA | EUR 818.4 |
GALNT4 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
LV638652 | ABM | 1.0 ug DNA | EUR 818.4 |
GALNT10 Antibody |
|||
24939-100ul | SAB | 100ul | EUR 468 |
GALNT10 Antibody |
|||
24940-100ul | SAB | 100ul | EUR 468 |
GALNT14 Antibody |
|||
40030-100ul | SAB | 100ul | EUR 468 |
Galnt11 antibody |
|||
70R-8825 | Fitzgerald | 50 ug | EUR 560.4 |
Description: Affinity purified rabbit polyclonal Galnt11 antibody |
GALNT10 Antibody |
|||
5279-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: GALNT10 Antibody: Protein glycosylation is an important biological process that is carried out by a large family of glycosyltransferases that catalyze the synthesis of oligosaccharides and glycoconjugates. Polypeptide GalNAc transferases initiate the synthesis of mucin-type oligosaccharides by transferring GalNAc from UDP-GalNAc to the hydroxyl group of either a serine or threonine residue on the polypeptide acceptor. Polypeptide galactoaminyltransferase 10 (GALNT10) belongs to the polypeptide N-acetylgalactosaminyl-transferase (pp-GalNAc-T) protein family. Following expression in insect cells, recombinant GALNT10 showed significant GalNAcT activity toward mucin-derived peptides, and it utilized both non-glycosylated and glycosylated peptide substrates. GALNT10 mRNA is highly expressed in several distinct hypothalamic, thalamic, and amygdaloid nuclei in mouse brain. At least four isoforms of GALNT10 are known to exist. |
GALNT10 Antibody |
|||
5279-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: GALNT10 Antibody: Protein glycosylation is an important biological process that is carried out by a large family of glycosyltransferases that catalyze the synthesis of oligosaccharides and glycoconjugates. Polypeptide GalNAc transferases initiate the synthesis of mucin-type oligosaccharides by transferring GalNAc from UDP-GalNAc to the hydroxyl group of either a serine or threonine residue on the polypeptide acceptor. Polypeptide galactoaminyltransferase 10 (GALNT10) belongs to the polypeptide N-acetylgalactosaminyl-transferase (pp-GalNAc-T) protein family. Following expression in insect cells, recombinant GALNT10 showed significant GalNAcT activity toward mucin-derived peptides, and it utilized both non-glycosylated and glycosylated peptide substrates. GALNT10 mRNA is highly expressed in several distinct hypothalamic, thalamic, and amygdaloid nuclei in mouse brain. At least four isoforms of GALNT10 are known to exist. |
GALNT10 Antibody |
|||
5281-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: GALNT10 Antibody: Protein glycosylation is an important biological process that is carried out by a large family of glycosyltransferases that catalyze the synthesis of oligosaccharides and glycoconjugates. Polypeptide GalNAc transferases initiate the synthesis of mucin-type oligosaccharides by transferring GalNAc from UDP-GalNAc to the hydroxyl group of either a serine or threonine residue on the polypeptide acceptor. Polypeptide galactoaminyltransferase 10 (GALNT10) belongs to the polypeptide N-acetylgalactosaminyl-transferase (pp-GalNAc-T) protein family. Following expression in insect cells, recombinant GALNT10 showed significant GalNAcT activity toward mucin-derived peptides, and it utilized both non-glycosylated and glycosylated peptide substrates. GALNT10 mRNA is highly expressed in several distinct hypothalamic, thalamic, and amygdaloid nuclei in mouse brain. At least four isoforms of GALNT10 are known to exist. |
GALNT10 Antibody |
|||
5281-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: GALNT10 Antibody: Protein glycosylation is an important biological process that is carried out by a large family of glycosyltransferases that catalyze the synthesis of oligosaccharides and glycoconjugates. Polypeptide GalNAc transferases initiate the synthesis of mucin-type oligosaccharides by transferring GalNAc from UDP-GalNAc to the hydroxyl group of either a serine or threonine residue on the polypeptide acceptor. Polypeptide galactoaminyltransferase 10 (GALNT10) belongs to the polypeptide N-acetylgalactosaminyl-transferase (pp-GalNAc-T) protein family. Following expression in insect cells, recombinant GALNT10 showed significant GalNAcT activity toward mucin-derived peptides, and it utilized both non-glycosylated and glycosylated peptide substrates. GALNT10 mRNA is highly expressed in several distinct hypothalamic, thalamic, and amygdaloid nuclei in mouse brain. At least four isoforms of GALNT10 are known to exist. |
GALNT14 antibody |
|||
70R-17413 | Fitzgerald | 50 ul | EUR 522 |
Description: Rabbit polyclonal GALNT14 antibody |
GALNT14 antibody |
|||
70R-7437 | Fitzgerald | 50 ug | EUR 560.4 |
Description: Rabbit polyclonal GALNT14 antibody |
GALNT13 antibody |
|||
70R-7449 | Fitzgerald | 50 ug | EUR 560.4 |
Description: Rabbit polyclonal GALNT13 antibody raised against the N terminal Of Galnt13 |
GALNT10 antibody |
|||
70R-5370 | Fitzgerald | 50 ug | EUR 560.4 |
Description: Rabbit polyclonal GALNT10 antibody raised against the N terminal Of Galnt10 |
GALNT12 Antibody |
|||
47372-100ul | SAB | 100ul | EUR 302.4 |
GALNT14 Antibody |
|||
1-CSB-PA009208GA01HU | Cusabio |
|
|
Description: A polyclonal antibody against GALNT14. Recognizes GALNT14 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC |
GALNT15 Antibody |
|||
1-CSB-PA009218GA01HU | Cusabio |
|
|
Description: A polyclonal antibody against GALNT15. Recognizes GALNT15 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC |
GALNT12 Antibody |
|||
1-CSB-PA814224LA01HU | Cusabio |
|
|
Description: A polyclonal antibody against GALNT12. Recognizes GALNT12 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200 |
GALNT15 Antibody |
|||
1-CSB-PA822698LA01HU | Cusabio |
|
|
Description: A polyclonal antibody against GALNT15. Recognizes GALNT15 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC; Recommended dilution: WB:1:1000-1:5000, IHC:1:20-1:200 |
GALNT14 Antibody |
|||
1-CSB-PA836212LA01HU | Cusabio |
|
|
Description: A polyclonal antibody against GALNT14. Recognizes GALNT14 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC; Recommended dilution: WB:1:1000-1:5000, IHC:1:20-1:200 |
GALNT11 Antibody |
|||
1-CSB-PA847687LA01HU | Cusabio |
|
|
Description: A polyclonal antibody against GALNT11. Recognizes GALNT11 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC, IF; Recommended dilution: IHC:1:20-1:200, IF:1:50-1:200 |
GALNT16 Antibody |
|||
1-CSB-PA850796LA01HU | Cusabio |
|
|
Description: A polyclonal antibody against GALNT16. Recognizes GALNT16 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB; Recommended dilution: WB:1:1000-1:5000 |
GALNT14 Antibody |
|||
DF13030 | Affinity Biosciences | 100ul | EUR 280 |
Description: Human,Mouse,Rat |
GALNT12 Antibody |
|||
E047372 | EnoGene | 100μg/100μl | EUR 255 |
Description: Available in various conjugation types. |
GALNT10 Antibody |
|||
E314623 | EnoGene | 200ul | EUR 275 |
Description: Available in various conjugation types. |
GALNT18 Antibody |
|||
E40PV1566 | EnoGene | 50ul | EUR 395 |
Description: Available in various conjugation types. |
GALNT12 Antibody |
|||
E306898 | EnoGene | 200ul | EUR 275 |
Description: Available in various conjugation types. |
GALNT14 Antibody |
|||
E306929 | EnoGene | 100ug/200ul | EUR 275 |
Description: Available in various conjugation types. |
GALNT14 Antibody |
|||
E306929b | EnoGene | 200ul | EUR 275 |
Description: Available in various conjugation types. |
GALNT13 Antibody |
|||
E310792 | EnoGene | 200ul | EUR 275 |
Description: Available in various conjugation types. |
GALNT14 Antibody |
|||
E94973 | EnoGene | 100μg | EUR 255 |
Description: Available in various conjugation types. |
GALNT14 Antibody |
|||
DF13030-100ul | Affinity Biosciences | 100ul | EUR 280 |
GALNT14 Antibody |
|||
DF13030-200ul | Affinity Biosciences | 200ul | EUR 350 |
GALNT1 Antibody |
|||
abx145974-100ug | Abbexa | 100 ug | EUR 469.2 |
GALNT7 antibody |
|||
23130-100ul | SAB | 100ul | EUR 468 |
GALNT2 antibody |
|||
22999-100ul | SAB | 100ul | EUR 468 |
GALNT3 antibody |
|||
39032-100ul | SAB | 100ul | EUR 302.4 |
GALNT9 Antibody |
|||
39419-100ul | SAB | 100ul | EUR 468 |
GALNT6 Antibody |
|||
40029-100ul | SAB | 100ul | EUR 468 |
Galnt3 antibody |
|||
70R-8653 | Fitzgerald | 50 ug | EUR 560.4 |
Description: Affinity purified rabbit polyclonal Galnt3 antibody |
GALNT6 antibody |
|||
70R-1908 | Fitzgerald | 100 ug | EUR 452.4 |
Description: Rabbit polyclonal GALNT6 antibody raised against the N terminal of GALNT6 |
GALNT2 antibody |
|||
70R-12773 | Fitzgerald | 100 ul | EUR 548.4 |
Description: Affinity purified Rabbit polyclonal GALNT2 antibody |
GALNT7 antibody |
|||
70R-12957 | Fitzgerald | 100 ul | EUR 548.4 |
Description: Affinity purified Rabbit polyclonal GALNT7 antibody |
GALNT7 antibody |
|||
70R-17415 | Fitzgerald | 50 ul | EUR 522 |
Description: Rabbit polyclonal GALNT7 antibody |
GALNT5 antibody |
|||
70R-7239 | Fitzgerald | 50 ug | EUR 560.4 |
Description: Rabbit polyclonal GALNT5 antibody |
GALNT6 antibody |
|||
70R-7465 | Fitzgerald | 50 ug | EUR 560.4 |
Description: Rabbit polyclonal GALNT6 antibody |
GALNT7 Antibody |
|||
1-CSB-PA009214GA01HU | Cusabio |
|
|
Description: A polyclonal antibody against GALNT7. Recognizes GALNT7 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB |
GALNT9 Antibody |
|||
1-CSB-PA862072LA01HU | Cusabio |
|
|
Description: A polyclonal antibody against GALNT9. Recognizes GALNT9 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB; Recommended dilution: WB:1:500-1:5000 |
GALNT2 Antibody |
|||
1-CSB-PA605995ESR1HU | Cusabio |
|
|
Description: A polyclonal antibody against GALNT2. Recognizes GALNT2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200 |
GALNT2 Antibody |
|||
1-CSB-PA605995ESR2HU | Cusabio |
|
|
Description: A polyclonal antibody against GALNT2. Recognizes GALNT2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC; Recommended dilution: WB:1:1000-1:5000, IHC:1:20-1:200 |
GALNT3 Antibody |
|||
1-CSB-PA613501ESR1HU | Cusabio |
|
|
Description: A polyclonal antibody against GALNT3. Recognizes GALNT3 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200 |
GALNT7 Antibody |
|||
1-CSB-PA773016LA01HU | Cusabio |
|
|
Description: A polyclonal antibody against GALNT7. Recognizes GALNT7 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC; Recommended dilution: WB:1:1000-1:5000, IHC:1:20-1:200 |
GALNT2 Antibody |
|||
DF14912 | Affinity Biosciences | 100ul | EUR 280 |
Description: Human,Mouse |
GALNT1 Antibody |
|||
DF15017 | Affinity Biosciences | 100ul | EUR 280 |
Description: Human,Mouse,Rat |
GALNT7 Antibody |
|||
DF15255 | Affinity Biosciences | 100ul | EUR 280 |
Description: Human,Mouse,Rat |
GALNT7 Antibody |
|||
E305002 | EnoGene | 100ug/200ul | EUR 275 |
Description: Available in various conjugation types. |
GALNT9 Antibody |
|||
E305028 | EnoGene | 100ug/200ul | EUR 275 |
Description: Available in various conjugation types. |
GALNT9 Antibody |
|||
E313444 | EnoGene | 100ug/200ul | EUR 295 |
Description: Available in various conjugation types. |
GALNT3 Antibody |
|||
E314038 | EnoGene | 100ug/200ul | EUR 295 |
Description: Available in various conjugation types. |
GALNT7 Antibody |
|||
E314460 | EnoGene | 100ug/200ul | EUR 295 |
Description: Available in various conjugation types. |
GALNT6 Antibody |
|||
E306900 | EnoGene | 100ug/200ul | EUR 275 |
Description: Available in various conjugation types. |
GALNT1 Antibody |
|||
E309559 | EnoGene | 200ul | EUR 275 |
Description: Available in various conjugation types. |
GALNT2 Antibody |
|||
E309560 | EnoGene | 200ul | EUR 275 |
Description: Available in various conjugation types. |
GALNT3 Antibody |
|||
E310793 | EnoGene | 200ul | EUR 275 |
Description: Available in various conjugation types. |
GALNT3 Antibody |
|||
E96596 | EnoGene | 100ul | EUR 255 |
Description: Available in various conjugation types. |
GALNT2 Antibody |
|||
DF14912-100ul | Affinity Biosciences | 100ul | EUR 280 |
GALNT2 Antibody |
|||
DF14912-200ul | Affinity Biosciences | 200ul | EUR 350 |
GALNT1 Antibody |
|||
DF15017-100ul | Affinity Biosciences | 100ul | EUR 280 |
GALNT1 Antibody |
|||
DF15017-200ul | Affinity Biosciences | 200ul | EUR 350 |
GALNT7 Antibody |
|||
DF15255-100ul | Affinity Biosciences | 100ul | EUR 280 |
GALNT7 Antibody |
|||
DF15255-200ul | Affinity Biosciences | 200ul | EUR 350 |
GALNT11 Antibody (HRP) |
|||
20-abx313734 | Abbexa |
|
|
GALNT12 Antibody (HRP) |
|||
20-abx308604 | Abbexa |
|
|
GALNT16 Antibody (HRP) |
|||
20-abx310083 | Abbexa |
|
|
anti- GALNT14 antibody |
|||
FNab03323 | FN Test | 100µg | EUR 658.5 |
Description: Antibody raised against GALNT14 |
GALNT11 Antibody (FITC) |
|||
20-abx313735 | Abbexa |
|
|
GALNT12 Antibody (FITC) |
|||
20-abx308605 | Abbexa |
|
|
GALNT16 Antibody (FITC) |
|||
20-abx310084 | Abbexa |
|
|
anti- GALNT7 antibody |
|||
FNab03325 | FN Test | 100µg | EUR 658.5 |
Description: Antibody raised against GALNT7 |
anti- GALNT9 antibody |
|||
FNab03326 | FN Test | 100µg | EUR 658.5 |
Description: Antibody raised against GALNT9 |
Galnt4 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
|||
K7515605 | ABM | 3 x 1.0 ug | EUR 451.2 |
GALNT11 Antibody (Biotin) |
|||
20-abx313736 | Abbexa |
|
|
GALNT12 Antibody (Biotin) |
|||
20-abx308606 | Abbexa |
|
|
GALNT16 Antibody (Biotin) |
|||
20-abx310085 | Abbexa |
|
|
GALNT4 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
K0835405 | ABM | 3 x 1.0 ug | EUR 451.2 |
Galnt4 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
|||
K3418205 | ABM | 3 x 1.0 ug | EUR 451.2 |
Human Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) ELISA Kit |
|||
abx387484-96tests | Abbexa | 96 tests | EUR 1093.2 |
GALNT12 Antibody, HRP conjugated |
|||
1-CSB-PA814224LB01HU | Cusabio |
|
|
Description: A polyclonal antibody against GALNT12. Recognizes GALNT12 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
GALNT15 Antibody, HRP conjugated |
|||
1-CSB-PA822698LB01HU | Cusabio |
|
|
Description: A polyclonal antibody against GALNT15. Recognizes GALNT15 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
GALNT14 Antibody, HRP conjugated |
|||
1-CSB-PA836212LB01HU | Cusabio |
|
|
Description: A polyclonal antibody against GALNT14. Recognizes GALNT14 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
GALNT11 Antibody, HRP conjugated |
|||
1-CSB-PA847687LB01HU | Cusabio |
|
|
Description: A polyclonal antibody against GALNT11. Recognizes GALNT11 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |